

Levamisole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.8
 28.09.2024
 5360094-00011
 Date of first issue: 19.12.2019

SECTION 1. IDENTIFICATION

Product identifier : Levamisole / Oxyclozanide Formulation

Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530

Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard

Reproductive toxicity : Category 2

Short-term (acute) aquatic

hazard

Category 2

Long-term (chronic) aquatic

hazard

Category 2

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :





Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.

H411 Toxic to aquatic life with long lasting effects.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use. P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.



Levamisole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.8
 28.09.2024
 5360094-00011
 Date of first issue: 19.12.2019

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Storage:

P405 Store locked up.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Classification | Concentration (% w/w) |
|--------------------------|------------|---|-----------------------|
| Kaolin | 1332-58-7 | | >= 5 -< 10 |
| Oxyclozanide | 2277-92-1 | Acute Tox. (Oral), 5 Repr., 2 STOT SE, (Oral)(Central nervous system), 2 STOT RE, (Brain, Liver), 2 Aquatic Acute, 1 Aquatic Chronic, 1 | >= 3 -< 5 |
| Levamisole hydrochloride | 16595-80-5 | Acute Tox. (Oral), 3 Repr., 2 STOT RE, (Oral)(Blood, Testis), 2 Aquatic Acute, 3 Aquatic Chronic, 3 | >= 1 -< 2,5 |
| Citric acid | 77-92-9 | Eye Irrit., 2A STOT SE, 3 | >= 1 -< 5 |

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.



Levamisole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.8
 28.09.2024
 5360094-00011
 Date of first issue: 19.12.2019

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Suspected of damaging the unborn child.

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and

Protection of first-aiders

delayed

: First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Chlorine compounds Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages



Levamisole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 28.09.2024 5360094-00011 Date of first issue: 19.12.2019

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation. Advice on safe handling : Do not breathe mist or vapors.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters



Levamisole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.8 28.09.2024 5360094-00011 Date of first issue: 19.12.2019

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis | |
|--------------------------|---------------------------|--|--|----------|--|
| Kaolin | 1332-58-7 | TWA (Respirable particulate matter) | 2 mg/m³ | ACGIH | |
| Oxyclozanide | 2277-92-1 | TWA | 0.4 mg/m3 (OEB 2) | Internal | |
| Levamisole hydrochloride | 16595-80-5 | TWA | 20 μg/m3 (OEB 3) | Internal | |
| | Further information: Skin | | | | |
| | | Wipe limit | 200 μg/100 cm ² | Internal | |

Engineering measures : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of

the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type

Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : liquid

Color : No data available

Odor : No data available



Levamisole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.8
 28.09.2024
 5360094-00011
 Date of first issue: 19.12.2019

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable



Levamisole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.8
 28.09.2024
 5360094-00011
 Date of first issue: 19.12.2019

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg

Method: Calculation method

Components:

Kaolin:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 5.000 mg/kg

Oxyclozanide:

Acute oral toxicity : LD50 (Rat): 3.519 mg/kg

Target Organs: Central nervous system

Acute toxicity (other routes of :

administration)

LDLo (sheep): 10 mg/kg

Application Route: Intravenous

Levamisole hydrochloride:

Acute oral toxicity : LD50 (Rat): 180 mg/kg

LD50 (Mouse): 223 mg/kg

LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5.400 mg/kg



Levamisole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.8 28.09.2024 5360094-00011 Date of first issue: 19.12.2019

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Kaolin:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Oxyclozanide:

Remarks : Not classified due to lack of data.

Levamisole hydrochloride:

Remarks : No data available

Citric acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Kaolin:

Species : Rabbit

Result : No eye irritation

Oxyclozanide:

Remarks : Not classified due to lack of data.

Levamisole hydrochloride:

Remarks : No data available

Citric acid:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Method : OECD Test Guideline 405



Levamisole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.8
 28.09.2024
 5360094-00011
 Date of first issue: 19.12.2019

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Oxyclozanide:

Routes of exposure : Dermal

Remarks : Not classified due to lack of data.

Levamisole hydrochloride:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Oxyclozanide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: positive

Test Type: Mouse Lymphoma

Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Application Route: Oral Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Levamisole hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative



Levamisole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.8
 28.09.2024
 5360094-00011
 Date of first issue: 19.12.2019

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro micronucleus test

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Oxyclozanide:

Remarks : Not classified due to lack of data.

Levamisole hydrochloride:

Species : Mouse Application Route : Oral Exposure time : 2 Years

NOAEL : 80 mg/kg body weight

Remarks : No significant adverse effects were reported

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 40 mg/kg body weight

Remarks : No significant adverse effects were reported

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Oxyclozanide:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat, male and female

Application Route: Oral

General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal

and postnatal development. Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study

Species: Rat



Levamisole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.8 28.09.2024 5360094-00011 Date of first issue: 19.12.2019

Application Route: Oral

General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal

and postnatal development. Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: LOAEL: 75 - 100 mg/kg body

weight

Result: No fetotoxicity., No teratogenic effects.

Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight Result: No fetotoxicity., No teratogenic effects., No effects on

fertility.

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 200 mg/kg body weight

Result: No fetotoxicity., No teratogenic effects.

Test Type: Development

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 100 mg/kg body weight

Result: No fetotoxicity., No teratogenic effects.

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 32 mg/kg body weight

Result: Fetotoxicity., Skeletal malformations.

Reproductive toxicity - As-

sessment

Suspected of damaging the unborn child.

Levamisole hydrochloride:

Effects on fertility : Test Type: Three-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Result: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 20 mg/kg body weight

Result: Fetotoxicity.

Test Type: Embryo-fetal development

Species: Rabbit



Levamisole / Oxyclozanide Formulation

Version **Revision Date:** SDS Number: Date of last issue: 30.09.2023 28.09.2024 5360094-00011 Date of first issue: 19.12.2019 2.8

Application Route: Oral

Developmental Toxicity: LOAEL: 40 mg/kg body weight

Result: Fetotoxicity.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Citric acid:

Effects on fetal development Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

STOT-single exposure

Not classified based on available information.

Components:

Oxyclozanide:

Routes of exposure : Oral

Target Organs : Central nervous system Assessment May cause damage to organs.

Citric acid:

Assessment May cause respiratory irritation.

STOT-repeated exposure

Not classified based on available information.

Components:

Oxyclozanide:

Target Organs Brain, Liver

Assessment May cause damage to organs through prolonged or repeated

exposure.

Levamisole hydrochloride:

Target Organs Blood, Testis

Assessment May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Oxyclozanide:

Species Rat NOAEL 9 mg/kg LOAEL 44,5 mg/kg **Application Route** Oral

3 Months Exposure time

Brain, Liver, spleen, Adrenal gland **Target Organs**



Levamisole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.8
 28.09.2024
 5360094-00011
 Date of first issue: 19.12.2019

Symptoms : Liver effects

Species: DogNOAEL: 5 mg/kgLOAEL: 25 mg/kgApplication Route: OralExposure time: 3 MonthsTarget Organs: Brain, Liver

Symptoms : blood effects, alteration in liver enzymes

Levamisole hydrochloride:

Species : Rat
NOAEL : 2,5 mg/kg
Application Route : Oral
Exposure time : 18 Months
Target Organs : Testis

Species : Dog LOAEL : 20 mg/kg Application Route : Oral Exposure time : 18 Months Target Organs : Blood

Species : Dog LOAEL : 40 mg/kg Application Route : Oral Exposure time : 3 Months

Citric acid:

Species : Rat

NOAEL : 4.000 mg/kg LOAEL : 8.000 mg/kg Application Route : Ingestion Exposure time : 10 Days

Aspiration toxicity

Not classified based on available information.

Components:

Oxyclozanide:

Not applicable

Experience with human exposure

Components:

Oxyclozanide:

Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central

nervous system depression

Levamisole hydrochloride:

Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypo-



Levamisole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.8
 28.09.2024
 5360094-00011
 Date of first issue: 19.12.2019

tension

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Oxyclozanide:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0,69 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

M-Factor (Acute aquatic tox-

icity)

M-Factor (Chronic aquatic

toxicity)

1

Levamisole hydrochloride:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37,3 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 64 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 1.535 mg/l

Exposure time: 24 h

Persistence and degradability

Components:

Oxyclozanide:

Stability in water : Hydrolysis: 50 %(156 d)

Method: OECD Test Guideline 111

Citric acid:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 97 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Bioaccumulative potential

Components:

Oxyclozanide:



Levamisole / Oxyclozanide Formulation

Version **Revision Date:** SDS Number: Date of last issue: 30.09.2023 28.09.2024 5360094-00011 Date of first issue: 19.12.2019 2.8

Partition coefficient: n-

octanol/water

log Pow: 3,99

pH: 7

Method: OECD Test Guideline 107

Citric acid:

Partition coefficient: n-

octanol/water

log Pow: -1,72

Mobility in soil

Components:

Oxyclozanide:

Distribution among environ-

mental compartments

log Koc: 4,83

Method: OECD Test Guideline 106

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number UN 3082

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(oxyclozanide)

Class 9 Ш Packing group Labels 9 Environmentally hazardous yes

IATA-DGR

UN/ID No. UN 3082

Proper shipping name Environmentally hazardous substance, liquid, n.o.s.

(Oxyclozanide)

9 Class Ш Packing group

Miscellaneous Labels

Packing instruction (cargo

aircraft)

Packing instruction (passen-

ger aircraft)

964

964

Environmentally hazardous yes

15 / 17



Levamisole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.8
 28.09.2024
 5360094-00011
 Date of first issue: 19.12.2019

IMDG-Code

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Oxyclozanide)

Class : 9
Packing group : III
Labels : 9

EmS Code : F-A, S-F Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

ANTT

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(oxyclozanide)

Class : 9
Packing group : III
Labels : 9
Hazard Identification Number : 90

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - : Not applicable

(LINACH)

Brazil. List of chemicals controlled by the Federal : Not applicable

Police

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 28.09.2024 Date format : dd.mm.yyyy



Levamisole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.8
 28.09.2024
 5360094-00011
 Date of first issue: 19.12.2019

Further information

Sources of key data used to compile the Material Safety

eChem Portal search results and European Chemicals Agen-

Internal technical data, data from raw material SDSs, OECD

Data Sheet cy, http://echa.europa.eu/

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8